Ameriprise
ALDX icon

Ameriprise’s Aldeyra Therapeutics ALDX Stock Holding History

Ameriprise’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,304
Closed -$183K – 4049
2025
Q4 		$183K Sell
35,304
-105
-0.3% -$539 ﹤0.01% 3942
2025
Q3 		$185K Buy
35,409
+9,146
+35% +$47.7K ﹤0.01% 3915
2025
Q2 		$101K Buy
+26,263
New +$67.9K ﹤0.01% 3884
2024
Q4 		– Sell
-12,580
Closed -$67.8K – 4075
2024
Q3 		$67.8K Buy
+12,580
New +$59.9K ﹤0.01% 3866
2024
Q2 		– Sell
-126,176
Closed -$413K – 3859
2024
Q1 		$413K Sell
126,176
-39,752
-24% -$131K ﹤0.01% 3481
2023
Q4 		$582K Sell
165,928
-32,083
-16% -$99K ﹤0.01% 3397
2023
Q3 		$1.32M Sell
198,011
-5,428
-3% -$40.3K ﹤0.01% 3019
2023
Q2 		$1.71M Buy
203,439
+60,007
+42% +$591K ﹤0.01% 2951
2023
Q1 		$1.42M Buy
143,432
+3,200
+2% +$22.6K ﹤0.01% 3001
2022
Q4 		$976K Buy
140,232
+102,032
+267% +$583K ﹤0.01% 3135
2022
Q3 		$204K Buy
38,200
+14,000
+58% +$84K ﹤0.01% 3699
2022
Q2 		$97K Sell
24,200
-6,600
-21% -$22.7K ﹤0.01% 3787
2022
Q1 		$137K Hold
30,800
– – ﹤0.01% 3812
2021
Q4 		$123K Sell
30,800
-15,100
-33% -$115K ﹤0.01% 3851
2021
Q3 		$403K Sell
45,900
-100
-0.2% -$918 ﹤0.01% 3473
2021
Q2 		$510K Buy
46,000
+22,100
+92% +$266K ﹤0.01% 3455
2021
Q1 		$284K Sell
23,900
-133,658
-85% -$1.54M ﹤0.01% 3614
2020
Q4 		$1.08M Sell
157,558
-79,116
-33% -$556K ﹤0.01% 3056
2020
Q3 		$1.75M Buy
236,674
+218,221
+1,183% +$1.41M ﹤0.01% 2733
2020
Q2 		$76K Buy
+18,453
New +$67.4K ﹤0.01% 3600
2019
Q1 		– Sell
-105,967
Closed -$879K – 3689
2018
Q4 		$879K Buy
105,967
+23,085
+28% +$237K ﹤0.01% 2988
2018
Q3 		$1.14M Buy
+82,882
New +$672K ﹤0.01% 3024

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise's ALDX Position: Q1 2026 in Review

Ameriprise sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 35,304 shares — an estimated $183K sold.

Ameriprise first reported a position in ALDX in Q3 2018 and held it in 22 quarters. The position peaked at $1.75M in Q3 2020. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Ameriprise reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 35,304 Aldeyra Therapeutics shares in Q1 2026, an estimated $183K.
  • Ameriprise first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 22 quarters.
  • Ameriprise's Aldeyra Therapeutics position peaked at $1.75M in Q3 2020.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.